Osimertinib Shows Significant OS Benefit in Patients With Resected, EGFRm NSCLC
Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and lead investigator for ADAURA, said the results erase any doubts about the use of osimertinib in early non–small cell lung cancer (NSCLC) for patients with EGFR mutations.
Group Highlights Discrepancies Between Claims, Survey Cost Data Among Medicare Patients
June 4th 2023With Medicare-aged Americans accounting for over 15% of the population and significant health care costs, stakeholders have leveraged various approaches, including the Medicare Current Beneficiary Survey, for estimating costs.
US Government Spent Far More on Costly HIV PrEP Development Than Previously Thought
June 2nd 2023According to new estimates, the US government spent between $143 million and $314 million in 2022 inflation-adjusted dollars funding the development of tenofovir disoproxil fumarate-emtricitabine. The previous estimate was around $50 million.
What We’re Reading: Biden Eyes Cohen for CDC; Bias in PFTs; US Birthrate Stays Flat
President Joe Biden has reportedly picked former North Carolina health chief Mandy Cohen, MD, MPH, as next head of the CDC; Black men were probably underdiagnosed with lung problems because of software bias; the US birthrate remains flat.
Stakeholder Analysis: Medicare Diabetes Prevention Program Awareness and Implementation
June 2nd 2023This article describes facilitators of and barriers to uptake of the underutilized Medicare Diabetes Prevention Program from the perspectives of health care providers and program suppliers in western Pennsylvania.